MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
14.19
-1.11
-7.25%
After Hours: 14.19 0 0.00% 19:34 08/14 EDT
OPEN
15.33
PREV CLOSE
15.30
HIGH
15.66
LOW
14.10
VOLUME
747.31K
TURNOVER
--
52 WEEK HIGH
16.91
52 WEEK LOW
6.19
MARKET CAP
533.84M
P/E (TTM)
-8.1683
1D
5D
1M
3M
1Y
5Y
1D
Stifel Nicolaus Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)
TipRanks · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at CTNM last week (0803-0807)?
Weekly Report · 5d ago
Weekly Report: what happened at CTNM last week (0727-0731)?
Weekly Report · 08/03 10:25
Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines
TipRanks · 07/31 18:55
Contineum Therapeutics Price Target Raised to $23.00/Share From $22.00 by RBC Capital
Dow Jones · 07/31 18:53
Contineum Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 07/31 18:53
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
Benzinga · 07/31 18:43
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.